Acurx Pharmaceuticals, Inc.
ACXP
$2.02
-$0.0109-0.54%
Headlines
4/25/2024
-
PR Newswire
4/23/2024
-
PR Newswire
4/15/2024
-
Ticker Report
4/13/2024
-
Ticker Report
3/22/2024
-
Zolmax
3/21/2024
-
Newsfile Corp. - News Releases
3/21/2024
-
Zolmax
3/19/2024
-
SeekingAlpha.com: All News
3/19/2024
-
Seeking Alpha - Healthcare
3/19/2024
-
Insider Monkey
3/19/2024
-
Ticker Report
3/19/2024
-
TipRanks Financial Blog
3/19/2024
-
GuruFocus
3/18/2024
-
SeekingAlpha
3/18/2024
-
Seeking Alpha: Transcripts
3/18/2024
-
InvestorPlace
3/18/2024
-
PR Newswire
3/15/2024
-
Benzinga
3/5/2024
-
Zolmax
3/4/2024
-
PR Newswire
2/29/2024
-
Zolmax
Buy Rating for Acurx Pharmaceuticals Amid Promising Phase 2 Results and Positive Regulatory Momentum
2/28/2024
-
TipRanks Financial Blog
2/27/2024
-
PR Newswire
2/23/2024
-
Globe Newswire
Filings
Friday, March 15, 2024
Sunday, December 31, 2023
Week of May 6 and 10 (est)
Price History
--
--
Corporate Info
917 533 1469
259 Liberty Avenue
Staten Island, NY 10305
Staten Island, NY 10305
Business Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel...
more